Financial Analysis: Coherus BioSciences (NASDAQ:CHRS) versus Scinai Immunotherapeutics (NASDAQ:SCNI)

Coherus BioSciences (NASDAQ:CHRS) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares Coherus BioSciences and Scinai Immunotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus BioSciences	$304.34 million	0.56	-$237.89 million	($0.08)	-18.38
Scinai Immunotherapeutics	$452,000.00	6.32	-$6.50 million	($239.17)	-0.01

Scinai Immunotherapeutics has lower revenue, but higher earnings than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.8% of Coherus BioSciences shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 7.6% of Coherus BioSciences shares are owned by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Coherus BioSciences has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Coherus BioSciences and Scinai Immunotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus BioSciences	0	1	3	0	2.75
Scinai Immunotherapeutics	0	0	0	0	0.00

Coherus BioSciences presently has a consensus price target of $5.38, indicating a potential upside of 265.65%. Given Coherus BioSciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Coherus BioSciences is more favorable than Scinai Immunotherapeutics.

Profitability

This table compares Coherus BioSciences and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coherus BioSciences	-0.15%	N/A	-24.44%
Scinai Immunotherapeutics	N/A	N/A	-30.48%

Summary

Coherus BioSciences beats Scinai Immunotherapeutics on 8 of the 13 factors compared between the two stocks.

About Coherus BioSciences

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.